Ngā kupu hautoa kōpae
Tohutoro APA (7th ed.)
Matsuura, S., Kita, K., Matsushita, K., Nagasaki, T., Suzuki, R., Yamamoto, Y., . . . Koshimizu, N. (2026). Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors. BMC.
I tāruatia paitia ki te papatopenga
Kua rahua te tārua ki te papatopenga
Tohutoru Kātū Chicago (17th ed.)
Matsuura, Shun, et al. Pretreatment Clinical and Hematological Predictors of Efficacy and Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancer Receiving First-line Chemotherapy Combined with Immune Checkpoint Inhibitors. BMC, 2026.
I tāruatia paitia ki te papatopenga
Kua rahua te tārua ki te papatopenga
Tohutoro MLA (9th ed.)
Matsuura, Shun, et al. Pretreatment Clinical and Hematological Predictors of Efficacy and Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancer Receiving First-line Chemotherapy Combined with Immune Checkpoint Inhibitors. BMC, 2026.
I tāruatia paitia ki te papatopenga
Kua rahua te tārua ki te papatopenga
Kia tūpato: Kāore pea ēnei kupu hautoa i te ōrite pū 100%.